














doi:10.101Accurate Targeting of Daily Intravenous Busulfan with
8-Hour Blood Sampling in Hospitalized Adult
Hematopoietic Cell Transplant Recipients
Rosa F. Yeh,1,2 Matthew A. Pawlikowski,1 David K. Blough,3,4 George B. McDonald,2,5
Paul V. O’Donnell,2,5 Andrew Rezvani,2,5 H. Joachim Deeg,2,5 Jeannine S. McCune2,3,4Daily intravenous (i.v.) busulfan is increasingly being used in hematopoietic cell transplantation (HCT) con-
ditioning regimens. Intravenous busulfan doses administered at the traditional frequency of every 6 hours can
be targeted (TBu) to a patient-specific concentration at steady state (Css) using therapeutic drug monitoring
(TDM). In this report, we describe our experiences with TDMof daily i.v. busulfan in an adult population, with
the specific aims of (1) evaluating covariates associated with busulfan clearance, and (2) assessing the feasi-
bility of TDM for outpatient administration of daily TBu with pharmacokinetic sampling over 6 hours. A ret-
rospective pharmacokinetic analysis was conducted in 87 adults receiving daily TBu as part of
cyclophosphamide followed by TBU (CY/TBU), fludarabine monophosphate (fludarabine) followed by
TBU, or TBU concurrent with fludarabine conditioning. The desired Css was achieved in 85% of patients re-
ceiving daily i.v. busulfan. Busulfan clearance was not associated with sex or age, but was associated with the
day of dosing and conditioning regimen (P5.0016). In patients receiving CY/TBU, no differences in clearance
were found between dosing days (P . .36); however, clearance decreased significantly in patients receiving
fludarabine-based regimens (P5.0016). Busulfan clearance and Css estimates from pharmacokinetic sampling
over 8, 11, or 24 hours were comparable (P. .4). However, pharmacokinetic modeling of individual patient
concentration-time data over 6 hours could not reliably estimate busulfan clearance or Css.
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tic drug monitoringINTRODUCTION
Several hematopoietic stem cell transplant (HCT)
conditioning regimens include high-dose busulfan. A
variety of clinical outcomes, including both toxicity
and lack of efficacy, are associated with the systemic
exposure of busulfan. Such outcomes are expressed
as area under the plasma concentration-time curve
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6/j.bbmt.2011.06.013pharmacodynamic associations of busulfan are affected
by other components such as the conditioning
regimen, the recipient’s age, and the underlying
disease (see previous reviews [1,2]). Over the past
decade, there have been an increasing number of
HCT centers that target busulfan (TBU) doses to
achieve the patient-specific busulfan exposure using
therapeutic drug monitoring (TDM) [2-5]. Dosing
of TBU with TDM is conducted by obtaining blood
samples after a dose based on body weight or body
surface area, quantitating the plasma concentrations,
and then modeling the individual concentration-
time data to estimate the individual patient’s busulfan
exposure and clearance. Using that individual’s busul-
fan clearance, subsequent doses are adjusted to
achieve the desired busulfan exposure because clear-
ance equals the dose divided by AUC and Css equals
AUC divided by dosing interval.
The recent trend in administering busulfan every
24 hours (ie, daily) from the traditional approach of
every 6-hour administration has led to the potential
for i.v. busulfan to be administered within an ambula-
tory clinic. Daily i.v. busulfan is typically administered265
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4 doses. Although less frequent dosing of i.v. busulfan
offers the potential advantage of outpatient adminis-
tration, it has the potential disadvantage of fewer doses
to conduct TDM and thus fewer opportunities to
achieve the desired busulfan exposure. When our cen-
ter initiated using daily i.v. busulfan, targeting of these
doses was necessary to allow for historic comparisons
with our TBU after oral administration. We sought
to identify the optimal initial weight-based dose of
daily i.v. busulfan to rapidly achieve the desired Css
and design a pharmacokinetic sampling schema that
allows for accurate daily busulfan dose targeting within
an outpatient setting. A logistically feasible outpatient
pharmacokinetic sampling schedule during the first
6 hours after the start of the daily 3-hour i.v. busulfan
infusion may reduce the need for clinical resources
(ie, nursing and laboratory staff time), increase patient
convenience, and potentially result in significant cost
savings. Thus, the objectives of this retrospective anal-
ysis in adults receiving daily i.v. busulfan are to:
(1) summarize our experience with TDM to TBU,
(2) evaluate covariates associated with busulfan clear-
ance, and (3) assess the feasibility of TDM in the out-
patient setting with pharmacokinetic sampling over
6 hours.METHODS
Study Population
This was a retrospective study of patients who
received HCT conditioning with daily i.v. busulfan
and TDM at the Seattle Cancer Care Alliance from
September 2004 to November 2009 under the aegis
of protocols approved by the FredHutchinson Cancer
Research Center institutional review board. All pa-
tients received TBU personalized using therapeutic
drug monitoring to achieve a patient-specific desired
average steady-state busulfan plasma concentration
(Css). Records were examined for demographic data
(age, sex, height, weight, body surface area) and clini-
cal data (disease, conditioning regimen). Standard
practice for prophylaxis of busulfan-induced seizures
was phenytoin.Conditioning Regimen
One of the following conditioning regimens was
administered: (1) CY followed by TBU (CY 60 mg/
kg/day i.v. on days 27 and 26, TBU on days 25 to
22); (2) fludarabine monophosphate (abbreviated as
fludarabine), followed by TBU (fludarabine 30 mg/
m2/day i.v. on days 29 through 26, TBU on days 25
to22, and rabbit antithymocyte globulin (rATG,Thy-
moglobulin) 0.5 mg/kg i.v. on day 23, 2.5 mg/kg on
day22, and 3 mg/kg on day21); and (3) TBU concur-rent with fludarabine (fludarabine 50mg/m2/day i.v. on
days 26 through 22, TBU on days 25 to 22, and
rATG 0.5 mg/kg i.v. on day 23, 2.5 mg/kg on day
22, and 3 mg/kg on day 21). All patients received
TBU for 4 days for a total of 4 doses.
Daily i.v. Busulfan Dosing
Administration of daily i.v. busulfan doses was
standardized regarding the time of administration
(5 a.m.), duration of busulfan infusion (3 hours), and
delivery of saline flush to clear the infusion line of
busulfan for consistency of daily i.v. busulfan adminis-
tration and pharmacokinetic sampling. The first bu-
sulfan dose (dose 1) was weight-based as determined
by the treatment protocol. Busulfan dose 1 was
3.2 mg/kg in the first cohort of patients, and was sub-
sequently increased to 4 mg/kg based on the average
clearance in that initial cohort. Busulfan dose 1 was
calculated using actual body weight if it was less than
ideal body weight, or adjusted ideal body weight
(AIBW, which equals 0.25 [actual weight – ideal
weight] 1 ideal weight) if actual body weight was
greater than ideal body weight [6]. The ideal body
weight in adults was calculated: for males 5 50 kg 1
(2.3 kg for each inch over 5 feet); for females 5
45.5 kg 1 (2.3 kg for each inch over 5 feet).
All subsequent busulfan doses were personalized to
achieve the desired patient-specific Css, which was
based on the treatment protocol and could be changed
by the attending physician.
Pharmacokinetic Sampling and Analysis
Blood samples (3 mL/sample) were collected in so-
dium heparin tubes after busulfan doses 1, 2, and 3.
These samples were drawn at the end of the 3-hour in-
fusion, and at 3.25, 4.5, 6, 8, 11, and 24 hours (ie, prior
to subsequent dose) after the beginning of the infusion.
The first sample was drawn at the end of the 3-hour
infusion, and no samples were drawn during the infu-
sion. Samples were stored on wet ice or refrigerated,
and transported to the laboratory. Plasma busulfan
concentrations were analyzed by gas chromatography
with mass selective detection as previously described
[3]. The dynamic range was from 62 to 4500 ng/mL
and the intraday and interday coefficient of variations
were less than 5% and 8%, respectively.
After quantitation of busulfan samples, the indi-
vidual patient’s concentration-time data were fit
using WinNonlin (version 5.2) via noncompartmen-
tal and compartmental modeling. The model selected
was determined based on visual inspection of the
model fit compared to the individual concentration-
time data. The AUC from time 0 to infinity
(AUC0-N) was calculated after each dose. In order
to provide same-day results, AUC0-N and its esti-
mated corresponding clearance were determined
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hours (first 22 patients) and 8 hours (subsequent 65 pa-
tients) after the beginning of infusion. Clearance and
Css were calculated based on the following equations:
clearance 5 dose divided by AUC and Css 5 AUC
divided by dosing interval. All clearances are reported
based on AIBW, which is the optimal body metric
for i.v. busulfan over a population of underweight to
obese patients [7,8]. Css was calculated as AUC0-N
multiplied by busulfan molecular weight (246.3 g/
mol) divided by the dosing interval (24 hours).
After calculation of the patient’s clearance, the target
dose for subsequent doses was calculated linearly
to achieve the target Css. Successful
TBU dosing was
confirmed after doses 2 and 3, with further dose
adjustments as needed.
In order to compare the body metrics of AIBW,
body surface area (BSA), and actual body weight for
determination of the initial busulfan dose, the amount
of busulfan administered for dose 1 was normalized by
AIBW (mg/kg), actual body weight (mg/kg), and BSA
(mg/m2). Each patient’s clearance was recalculated
using AIBW (mL/min/kg), actual body weight (mL/
min/kg), and BSA (mL/min/m2). According to body
mass index (BMI), 4 weight categories were defined:
underweight (BMI \18 kg/m2), normal (BMI 18-
26.9 kg/m2), obese (BMI 27-35 kg/m2), and severely
obese (BMI .35 kg/m2) [7,9]. BMI was calculated as
weight (kg)/height2 (m2). Body metric-normalized
clearances were compared by 1-way analysis of
variance (ANOVA).
For this retrospective analysis, all concentration-
time data were reanalyzed in WinNonlin to evaluate
the bias and precision of our current clinical practice
(ie, sampling over 8 hours) for daily i.v. TBU. For pa-
tients targeted to a concentration of 900 ng/mL, for
the purpose of this analysis 900% 6 5% was consid-
ered to be within the target range.Statistical Methods
Descriptive statistics were used to summarize our
experience with therapeutic drug monitoring of daily
i.v. TBU. Each participant’s average busulfan clearance
based on AIBW was calculated from busulfan clear-
ance after doses 1, 2, and 3. The data were normally
distributed.
The difference in busulfan clearance between
doses was evaluated using the mixed procedure linear
regression model, taking into account repeated mea-
surements within subjects, with sex, age, dose number,
and conditioning regimen as covariates. The interdose
variability was calculated by determining the percent
(%) change in busulfan clearance. For example, the dif-
ference between busulfan clearance from dose 1 to




To calculate the shortest duration of pharmacoki-
netic sampling, the percent difference in busulfan Css
was calculated using the pharmacokinetic sampling
over 24 hours as the reference value. For example,
the difference between busulfan Css estimated from 8
hours (ie, our current clinical practice) to busulfan





To evaluate the effect of sampling duration on
clearance, a separate mixed procedure linear regres-
sion model taking into account repeated measure-
ments was used. This analysis was conducted with
1-compartmental and noncompartmental model
data, including sampling duration (ie, 24, 11, 8, and
6 hours) as an additional covariate, with sampling
over 24 hours as the reference value.
All statistical analyses were performed using SAS
9.2 (Cary, NC). A P value of \.05 was considered
significant for all evaluations.RESULTS
Patient Population
Patient pretransplantation demographics and
HCT characteristics are described in Table 1. All pa-
tients had hematologic diseases or malignancies. The
mean age was 50.5 6 11.0 years (range: 19.1-65.5).
The actual body weight was 80.3 6 20.2 kg (range:
45.2-170.7), and AIBW was 68.2 6 10.9 kg (range:
47.8-103.5). Sixty percent (52 of 87) of the patients
were male. The majority received either TBU and flu-
darabine 6 rATG (51.7%) or CY followed by TBU
(48.3%) as HCT conditioning. Fludarabine was fol-
lowed by TBU in 29 patients and TBU was given con-
currently with fludarabine in 16 patients. No other
antineoplastic agents or irradiation was given immedi-
ately before or concomitantly with TBU. All patients
received daily i.v. busulfan, which was targeted to
various Css. All patients had a narrow desired busulfan
Css range, between 800 and 1000 ng/mL (Table 1).
Initial Dosing Weight and Success with
Achieving Desired Busulfan Css
Initially, a daily i.v. busulfan dose of 3.2 mg/kg was
administered for dose 1. An interim analysis demon-
strated that few patients achieved a busulfan Css of
800 to 1000 ng/mL with this dose and the first daily
i.v. busulfan dose was raised to 4 mg/kg. This higher
dose of 4 mg/kg has been shown to achieve a busulfan




Age (years) 50.5 ± 11.0
Actual body weight (kg) 80.3 ± 20.2
Adjusted ideal body weight (kg) 68.2 ± 10.9
Conditioning regimen
CY/TBU 42 (48.3%)
TBU+ fludarabine ± rATG
Fludarabine followed by TBU 29 (33.3%)




To 900 5 (5.7%)
950-1000 1 (1.1%)
Diagnosis
Acute myeloid leukemia 22 (25.3%)
Myelofibrosis 22 (25.3%)
Myelodysplastic syndrome 21 (24.1%)
Chronic myelomonocytic leukemia 9 (10.3%)
Acute myeloid leukemia/myelodysplastic syndrome 7 (8.0%)
Chronic myeloid leukemia 2 (2.3%)
Polycythemia vera 2 (2.3%)
Agnogenic myeloid metaplasia 1 (1.1%)
Chronic lymphocytic leukemia 1 (1.1%)
TBU indicates targeted busulfan; rATG, rabbit antithymocyte globulin;
Css, concentration at steady state.
*Data shown in n (%) or mean + standard deviation (SD).
268 Biol Blood Marrow Transplant 18:265-272, 2012R. F. Yeh et al.Css of 800 to 1000 ng/mL in a larger percentage of pa-
tients [2]. Sixty-two of the 87 patients received 4 mg/kg
for dose 1. The ability to achieve the desired Css with
this higher dose 1 and TBU using TDM is reported in
Table 2. After dose 1, the desired Css was achieved in
22.6% (14 of 62); 37.1% (23 of 62) were below their de-
sired Css; and 40.3% (25 of 62) were above their desired
Css. No patients required a dose change of.50% to at-
tain the target Css.Table 2. Success of Targeting of Daily i.v. Busulfan with Pharmaco
Dose 1
Dose based on 4 mg/kg AIBW
Number evaluable 62
Average Css (ng/mL)* 903 ± 169
Coefficient of variation in Css 18.7%
Success of targeting, as number (%)
of patients achieving desired Css*:
Overall population
Achieved target 14 (22.6%)
Below target 23 (37.1%)
Above target 25 (40.3%)
800-900 ng/mL 43
Achieved target 7 (16.3%)
Below target 16 (37.2%)
Above target 20 (46.5%)
800-1000 ng/mL 15
Achieved target 7 (46.7%)
Below target 5 (33.3%)
Above target 3 (20.0%)
To 900 ng/mL (±5%) 4
Achieved target 0
Below target 2 (50.0%)
Above target 2 (50.0%)
AIBW indicates adjusted ideal body weight; Css, concentration at steady-state
*Data shown in number (%) or mean 6 standard deviation.We also compared using the different bodymetrics
of AIBW, actual body weight, and BSA to calculate the
initial daily i.v. busulfan dose. In the 62 patients receiv-
ing 4 mg/kg by AIBW for dose 1, the median (range)
amount of busulfan administered for dose 1 was 3.6
(range: 2.3-4.0) mg/kg by actual body weight and
143 (range: 122-159) mg/m2 by BSA. Initial busulfan
clearances at dose 1 by different weight metrics and
BMI-based weight category are shown in Table 3.
Clearance was significantly different between the
different BMI weight categories when normalized by
actual body weight (P 5 .001), but not when normal-
ized by AIBW (P 5 .236) or BSA (P 5 .822).
Therapeutic drug monitoring after dose 1 substan-
tially increased the number of patients within the tar-
get range, both in the overall population with various
desired Css and by the specific Css ranges. For example,
in the overall population, therapeutic drug monitoring
after dose 1 led to an additional 51.2% of patients
achieving the desired Css, with 22.6% within target
after dose 1 (ie, 4 mg/kg) and 73.8% within target after
dose 2 (ie, daily i.v. TBU based on therapeutic drug
monitoring after dose 1). TDM after dose 3 further in-
creased the number of patients within the target range,
with the target Css being achieved in 85.2% of the pop-
ulation.Busulfan Pharmacokinetics
After doses 1, 2, and 3, the average (6SD, range)
clearance was 3.22 6 0.63 (range: 1.85-5.23), 3.12 6
0.57 (range: 1.71-4.49), and 3.07 6 0.60 (range: 1.82-
4.63), respectively. The data are also presented as box
and whisker plots of busulfan clearance (mL/min/kg
of AIBW) after doses 1, 2, and 3 in Figure 1. Thekinetic Sampling over 8 Hours after Doses 1, 2, and 3
Dose 2 Dose 3
Dose 1 clearance Dose 2 clearance
61 61
873 ± 110 872 ± 111
12.6% 12.8%
45 (73.8%) 52 (85.2%)
6 (9.8%) 3 (4.9%)
10 (16.4%) 6 (9.8%)
42 42
29 (69.0%) 37 (88.1%)
6 (14.3%) 2 (4.8%)
7 (16.7%) 3 (7.1%)
15 15
13 (86.7%) 13 (86.7%)
0 0
2 (13.3%) 2 (13.3%)
4 4
3 (75.0%) 2 (50.0%)
0 1 (25.0%)
1 (25.0%) 1 (25.0%)
.
Table 3. Initial Busulfan Clearance at Dose 1 by Different Weight Metrics and Body Mass Index–Based Weight Category
Underweight Normal Obese Severely Obese P Value
Number, N (%) 0 (0) 49 (56.3) 32 (36.8) 6 (6.9) —
mL/min/kg AIBW* ND 3.18 ± 0.68 (1.85-5.23) 3.19 ± 0.55 (2.17-4.30) 3.64 ± 0.60 (2.70-4.48) .236
mL/min/kg ABW* ND 3.01 ± 0.62 (1.86-4.55) 2.62 ± 0.46 (1.60-3.76) 2.35 ± 0.46 (1.71-2.98) .001
mL/min/m2 BSA* ND 114 ± 24 (69-177) 113 ± 19 (71-158) 119 ± 23 (85-142) .822
AIBW indicates adjusted ideal body weight; ABW, actual body weight; BSA, body surface area; ND, no data.
*Data shown as mean 6 SD (range).
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sented by coefficient of variation (SD/mean), ranged
from 18.2% to 19.6%.
The interdose or within-patient variability was
also characterized to help guide how many days of
TDM are needed for daily i.v. TBU in future studies.
TDM was not conducted after dose 2 in 3 patients
and after dose 3 in 11 patients. Therefore, interdose
variability of busulfan clearance could be calculated
in 78 patients. Busulfan clearance was calculated using
1-compartment modeling of pharmacokinetic data
obtained over 24 hours. The interdose coefficient of
variation in busulfan clearance was an average 6.0%
(range: 1.3%-17.6%). The change in busulfan clear-
ance between doses is shown in Table 4 and Figure 2.
The majority of patients (ie, 49 of 76, 64.5%) had
a minimal (ie, #10%) change in clearance from dose
1 to dose 3. A greater than 10% change was chosen
as potentially clinically significant in consideration of
the narrow target Css of this patient population.
Twenty-one patients (27.6%) had a .10% decrease
in busulfan clearance, and 6 patients (7.9%) had
a .10% increase in busulfan clearance.
We sought to identify if any clinically available
factors were associated with busulfan clearance. Clear-
ance was not associated with sex or age, but was
associated with dosing day and conditioning regimenFigure 1. Median daily i.v. busulfan clearance (mL/min/kg of AIBW)
after doses 1, 2, and 3. Legend: Box and whiskers represent 25th and
75th percentiles (interquartile range) and 10th and 90th percentiles,
respectively. AIBW, adjusted ideal body weight.(P 5 .0016). For patients receiving CY followed by
TBU, there was minimal interdose variability in busul-
fan clearance with the majority of patients (30 of 37, or
81.1%) having #10% change in busulfan clearance.
There was greater interdose variability in busulfan
clearance in those receiving TBU with fludarabine.
Specifically, a minimal (#10%) interdose change in
busulfan clearance was observed in 56% (14 of 25)
and 35.7% (5 of 14) of patients conditioned with
fludarabine followed by TBU or with TBU adminis-
tered concurrently with fludarabine, respectively. Sim-
ilar results were found using both the 1-compartment
and noncompartmental model with sampling over 8
hours (data not shown).Differences in Busulfan Css and Clearance
Estimates Based on Sampling Duration
The differences in busulfan Css estimates based on
sampling duration are shown in Figure 3. Using both
1-compartmental and noncompartmental modeling,
sampling over 8, 11, or 24 hours were comparable
(P . .4), although 1-compartmental Css estimates
from sampling over 8 and 11 hours were most similar
to 24 hour sampling with mean 6 SD differences of
20.18%6 1.91% and20.32%6 1.80%, respectively.
Decreased sampling duration over 6 hours was less
reliable, with differences in Css estimates ranging
from 212.4% to 19.0% (1-compartment; P\ .001)
and225.7% to111.8% (noncompartment; P\ .001)
compared with sampling over 24 hours.
To further evaluate if sampling duration was
adequate, we also evaluated the effect of sampling
duration on busulfan clearance estimates using time
as a covariate. Using the 1-compartment model, differ-
ences in clearance estimates were similar when sam-
pling over 11 and 8 (P 5 .253), but not 6 hours (P 5
.03). Using noncompartmental modeling, clearance
was significantly affected by sampling duration (P\
.0001), and sampling over 6 hours was significantly
different compared with sampling durations of 8, 11,
and 24 hours (P\ .01).DISCUSSION
There are several key findings of this retrospective
analysis of adults receiving daily i.v. busulfan as part of
Table 4. Dose-to-Dose Variability of Daily i.v. Busulfan Clearance (CL)*‡
Dose 1 to 2 Dose 2 to 3 Dose 1 to 3
All patients
Number (N) 84† 76† 76†
% Change in CL 23.1 ± 8.7 (227.6 to +16.7%) 21.4 ± 8.0 (215.4 to + 24.1%) 24.6 ± 9.4 (225.1 to + 16.1%)
>10% increase 6 (7.1) 6 (7.9) 6 (7.9)
Minimal (#10%) change 61 (72.6) 61 (80.3) 49 (64.5)
>10% decrease 17 (20.2) 9 (11.8) 21 (27.6)
CY followed by TBU
N 40 37 37
% Change in CL, mean ± SD (range) 20.6 ± 7.3 (217.5 to +15.9%) 20.3 ± 7.5 (210.2 to +24.1%) 21.0 ± 7.6 (216.5% to +14.2%)
>10% increase 4 (10.0) 4 (10.8) 4 (10.8)
#10% change 33 (82.5) 31 (83.8) 30 (81.1)
>10% decrease 3 (7.5) 2 (5.4) 3 (8.1)
Fludarabine, then TBU
N 29 25 25
% Change in CL 25.6 ± 8.3 (224.4 to +16.7%) 21.1 ± 9.3 (215.4 to +20.5%) 27.1 ± 9.1 (222.1 to +16.1%)
>10% increase 1 (3.4%) 2 (8.0%) 2 (8.0%)
Minimal (#10%) change 19 (65.5%) 19 (76.0%) 14 (56.0%)
>10% decrease 9 (31.0%) 4 (16.0%) 9 (36.0%)
Fludarabine concurrent with TBU
N 15 14 14
% Change in CL 25.1 ± 11.1 (227.6 to +16.1%) 24.9 ± 5.9 (213.6 to +7.2%) 29.7 ± 11.2 (225.1 to +9.4%)
>10% increase 1 (6.7%) 0 0
Minimal (#10%) change 9 (60.0%) 11 (78.6%) 5 (35.7%)
>10% decrease 5 (33.3%) 3 (21.4%) 9 (64.3%)
TBU indicates targeted busulfan; AIBW, adjusted ideal body weight.
*Clearance as mL/min/kg of AIBW.
†Data not available in 3 patients after dose 2 and 11 patients after dose 3.
‡Data presented as N (%) or mean 6 SD (range).
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Css can be achieved with TDM over a short enough
time interval (ie, 8 hours) to personalize the next dose
of daily i.v. busulfan. Second, there is minimal dose-
to-dose (ie, interdose) variability of busulfan clearance,
which could reduce the number of doses that need
TDM relative to oral busulfan. Finally, 8 hours is the
minimal sampling duration to accurately target busul-
fan Css with the current pharmacokinetic modeling
technique of analyzing individual patient busulfan
concentration-time data.
Rapid achievement of the desired busulfan Css is
critical for improving clinical outcomes with TDM
of busulfan [10]. Therefore, it is important to choose
the optimal initial daily i.v. busulfan dose, which is
based on AIBW. Dosing based on AIBW is optimal
over a population with a wide range of BMI categories
because busulfan clearance significantly varies among
different BMI categories (ie, underweight, normal,
obese, and severely obese) when expressed relative to
the actual body weight. The differences are minimized
when busulfan clearance is normalized by AIBW and/
or BSA [7,8]. Therefore, dosing i.v. busulfan by AIBW
or BSA is optimal as they are associated with less
interpatient variability in busulfan clearance, and in
turn, as is the resulting busulfan Css.
In patients whose desiredCss is 800 to 1000 ng/mL,
the daily I.V. busulfan dose of 4 mg/kg led to a higher
percentage of patients (63%) achieving the desired Css
than those receiving 3.2 mg/kg (11%) [2]. Further-
more, fewer patients needed large (ie, .50%) modifi-cations in the daily i.v. busulfan dose when the initial
dose was 4 mg/kg. The subsequent daily i.v. busulfan
doses were targeted using TDM. The majority of the
population achieved the desired Css with sampling
over 8 hours using pharmacokinetic modeling of an
individual patient’s concentration-time data. This al-
lowed for doses 2, 3, and 4 to be personalized to
achieve the desired Css. Daily i.v. busulfan dose target-
ing was conducted as part of studies administering CY
(CY) before daily i.v. busulfan (ie, CY/TBU) [11] and
administering daily i.v. BU combined with the nucle-
oside analog, fludarabine, in hopes of continued im-
proved outcomes with busulfan-containing regimens
[12,13]. These desired Css ranges were chosen based
on our historic experience targeting oral busulfan,
with 800 to 900 ng/mL being the desired Css for
CY/TBU [14] and 800 to 1000 ng/mL being the
desired Css for fludarabine/
TBU [13].
Interindividual variability of busulfan clearance
was 19%, which agrees with previous reports rang-
ing from 16% to 34% [2,15-19]. With daily i.v.
busulfan administration, busulfan clearance decreased
minimally (average of 24.6%) from dose 1 to dose 3.
However, in the limited population of 15 patients
who received TBU concomitant with fludarabine,
busulfan clearance progressively decreased from dose
1 to 3 (average of 29.7%). This decreased clearance
would lead to a slight increase in busulfan Css during
a 4-day course of daily i.v. busulfan, with unclear
clinical significance. Healthcare practitioners who
conduct TDM in patients conditioned with TBU
Figure 2. Minimal interdose variability in daily i.v. busulfan clearance by
conditioning regimen. Interdose busulfan clearance (mL/min/kg of
AIBW) calculated as [(CLdose2 – CLdose 1)/CLdose1]  100% (see Statis-
tical Methods for additional details). Box and whiskers represent 25th
and 75th percentiles (interquartile range) and 10th and 90th percentiles,
respectively. TBU, targeted busulfan; AIBW, adjusted ideal body weight.
(A) CY followed by TBU. P . .36 for all comparisons. (B) Fludarabine
followed by TBU. (C) TBU concurrent with fludarabine.
Figure 3. Feasibility of shorter pharmacokinetic sampling intervals to
estimate Css. Css, concentration at steady-state. Percent difference in
Css estimated from pharmacokinetic samples obtained over 24 hours
(gold standard) compared with that from shorter time intervals (ie,
11, 8, and 6 hours). First sample obtained at the end of a 3-hour infusion.
Css estimated using either 1-compartment model or noncompartmental
analysis. Box and whiskers represent 25th and 75th percentiles
(interquartile range) and 10th and 90th percentiles, respectively.
Biol Blood Marrow Transplant 18:265-272, 2012 271Targeting Daily i.v. Busulfan in Adultsconcomitant with fludarabine should target the daily
i.v. busulfan dose to the lower portion of their desired
Css range to compensate for this decreased clearance
and its resultant higher Css.
Recent pharmacodynamic analyses suggest that
a busulfan Css .1026 ng/mL is associated with higher
nonrelapse mortality (NRM) in patients receivingdaily i.v. busulfan with total body irradiation (TBI)
and concomitant fludarabine [17]. Many studies of
fludarabine/busulfan regimens incorporate TBM
[5,13], and thus daily i.v. TBU is expected to continue.
Achieving a narrow desired busulfan Css with TDM
should also be balanced with the expense of an
inpatient admission, which is necessitated when the
pharmacokinetic sampling duration is 8 hours or
longer. In this analysis, clearance estimates were
similar with pharmacokinetic sampling over 8, 11, and
24 hours from the beginning of the 3-hour infusion of
daily i.v. busulfan.However, a 6-hour samplingduration
resulted in more variable Css estimates with noncom-
partmental or 1-compartmental modeling of individual
concentration-timedata (Figure3).Ofnote, nopharma-
cokinetic samplesweredrawnduring the daily i.v. busul-
fan infusion. Accurate estimates of daily i.v. busulfan
clearance can be achieved with a 6-hour sampling dura-
tion if post-Bayesian estimates are obtained by incorpo-
rating an individual patient’s concentration-time data
into a population pharmacokinetic model [8]. Bayesian
pharmacokinetic modeling can be conducted using an
individual patient’s concentration-time data with a pop-
ulation pharmacokinetic model to estimate that individ-
ual’s busulfan clearance [20,21].This tool can reduce the
sampling duration to 6 hours, but prospective validation
is needed [8]. A Bayesian approach has also successfully
been usedwithTDMofCY inHCTrecipients [22,23]
and mycophenolate mofetil in renal transplant
recipients [24].
In summary, an initial daily i.v. busulfan dose of
4 mg/kg with TDM can successfully achieve the
272 Biol Blood Marrow Transplant 18:265-272, 2012R. F. Yeh et al.desiredCss, even over narrowCss ranges. TDMof daily
i.v. BU should be conducted by sampling over a mini-
mum of 8 hours after the start of infusion, following at
least the initial dose because of minimal dose-to-dose
variability of busulfan clearance in most patients.
As more centers implement TDMof daily i.v. busulfan
to improve outcomes, prospective validation of
a Bayesian population pharmacokinetic approach
should allow for a transition to a more convenient
and economical outpatient sampling schedule.ACKNOWLEDGMENTS
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